



FOR IMMEDIATE RELEASE

Diatron To Offer Advanced Hematology Analyzer in the U.S.

Device targets sales in the growing U.S. Physician Office Laboratory market

KANSAS CITY, MO April 5, 2012 – Diatron Group (Diatron), a Swiss-based company and global provider of hematology and clinical chemistry analyzers, has received FDA 510(k) premarket approval for its advanced laser optics hematology analyzer. The approval allows Diatron to begin commercial operations for the device in the U.S.

The analyzer, Abacus 5, is the latest and most advanced model of Diatron's range of hematology analyzers. The system uses a patented long-life diode laser-based optical measurement technology that ensures optimal performance using a high-tech flow cell. Adding to the instrument's technology advantages is the efficient and easy-to-use operating system and an optional autoloader with the capability of 100 samples.

"The Abacus 5 five-part differential hematology analyzer, is the most sophisticated optical instrument of its kind in a compact and efficient benchtop system. The instrument's advanced laser optics provide enhanced cellular analysis and detailed white blood cell differentials found in much larger and more expensive instruments," said Diatron Group CEO Jim Schepp.

Diatron's continued growth is based on the strong expansion opportunities available for its products in the multibillion dollar U.S. medical device market, which has been growing steadily over the past decade. The devices manufactured by Diatron, a portfolio company of global private equity firm The Riverside Company, are favored by laboratories worldwide because of their ease of use, quality and value.

"This approval marks a big step forward for Diatron Group," said Schepp. "The Abacus 5 Hematology instrument is now available for commercial sales here in the United States and is a perfect complement to our line of clinical chemistry instruments that we sell through distributors to physician offices and small-to medium-size hospital laboratories and clinics."

About Diatron

Diatron, founded in 1989, develops, manufactures and markets compact hematology analyzers and reagents for the human medical and veterinary markets. The company is well positioned with an extensive R&D/Engineering team and a new, modern production facility based in Budapest, Hungary. The company's Metrolab Division is based in Buenos Aires, Argentina and has been engineering and manufacturing clinical chemistry instruments for more than 25 years. For more information, please visit www.diatron.com.

About The Riverside Company

The Riverside Company is a global private equity firm focused on acquiring growing businesses valued at up to \$200 million (€200 million in Europe). Since its founding in 1988, Riverside has invested in more than 280 transactions. The firm's international portfolio includes 80 companies, and it has more than \$3 billion/€2.5 billion in assets under management.

www.riversidecompany.com